Clementia falls on Phase II data for rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) lost $4.05 (21%) to $14.85 on Wednesday after reporting data from a Phase II trial of palovarotene to treat fibrodysplasia ossificans progressiva (FOP). FOP is a rare, genetic bone disease characterized by heterotopic ossification (HO), or bone formation outside of

Read the full 444 word article

User Sign In